Cannabigerol Oil for Adolescents With ADHD (CAN-ADHD)
Key facts
- Who runs it
- Universidade do Sul de Santa Catarina
- Where
- Brazil1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 1/2
- People taking part
- 60 people, planned
- Started
- 1 May 2026
- Expected to end
- 18 Dec 2026
- Type of study
- Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
- Treatments tested
- Experimental: Full-spectrum CBG oil 30 mg/mL
- Placebo oil (MCT oil)
- Record updated
- 18 May 2026
Who can take part
- Age
- 12 years to 17 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (12)Hide the full registry criteria
Who can take part
- Adolescents aged 12 to 17 years
- Diagnosis of Attention-Deficit/Hyperactivity Disorder (ADHD) confirmed using the SNAP-IV (Swanson, Nolan and Pelham Questionnaire, version IV)
- History of previous treatment with pharmacological or non-pharmacological interventions without significant improvement of symptoms
- Absence of severe psychiatric disorders or relevant physical comorbidities
- Ability of the participant and legal guardian to understand study procedures
- Provision of written informed consent by the legal guardian and assent by the adolescent
Who cannot take part
- Use of cannabinoid-based substances (natural or synthetic) within 30 days prior to study initiation
- History of intolerance or adverse reactions to cannabis-derived compounds (e.g., confusion, paranoia, pruritus, excessive drowsiness, vomiting, diarrhea, or seizures)
- Presence of severe psychiatric disorder not related to ADHD
- Moderate to severe cognitive impairment
- Presence of any significant physical comorbidity
- Inability or unwillingness to complete study procedures or questionnaires adequately
Eligibility questionnaire
From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Age
- Attention-deficit/hyperactivity disorder
This trial is currently available in Brazil.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This study aims to evaluate the potential effects of full-spectrum cannabigerol (CBG) oil on cognitive and behavioral symptoms in adolescents diagnosed with Attention-Deficit/Hyperactivity Disorder (ADHD). ADHD is a neurodevelopmental disorder characterized by inattention, hyperactivity, and impulsivity, often associated with impairments in academic, social, and emotional functioning.
Read full original descriptionShow less
This is a randomized, double-blind, placebo-controlled clinical trial with a parallel design. A total of 60 adolescents aged 12 to 17 years, diagnosed with ADHD and with insufficient response to previous treatments, will be enrolled and randomly assigned to either the intervention group or the placebo group.
Participants in the intervention group will receive full-spectrum CBG oil (30 mg/mL), administered sublingually, with individualized dosing determined by the study physician and adjusted through weekly monitoring. The placebo group will receive an inert oil matched in appearance and administration conditions.
The intervention will last for 12 weeks, including in-person clinical assessments at baseline, week 6, and week 12, as well as weekly remote monitoring to assess adherence, safety, and dose adjustments.
Primary outcomes will include changes in ADHD symptom severity measured by the SNAP-IV scale. Secondary outcomes will assess quality of life, emotional symptoms, sleep patterns, and safety profile.
This study aims to contribute to the scientific understanding of cannabinoids as a potential therapeutic option for adolescents with ADHD, a population for which current evidence remains limited.
The 2 groups in the trial
- Full-spectrum CBG oil 30 mg/mLTreatment being tested
Participants allocated to this arm will receive sublingual administration of full-spectrum cannabigerol oil for 12 weeks under double-blind conditions. The formulation contains cannabigerol, cannabidiol, and a low concentration of tetrahydrocannabinol. Clinical assessments will be performed at baseline, Week 6, and Week 12, with weekly remote monitoring to evaluate adherence, tolerability, adverse events, and the need for dose adjustments.
Treatment: Experimental: Full-spectrum CBG oil 30 mg/mL
- Placebo (MCT oil)Placebo, for comparison
Participants allocated to this arm will receive sublingual administration of placebo oil for 12 weeks under double-blind conditions. The placebo formulation consists of medium-chain triglyceride (MCT) oil matched to the experimental product in appearance, viscosity, color, and administration schedule. Clinical assessments will be performed at baseline, Week 6, and Week 12, with weekly remote monitoring to evaluate adherence, tolerability, adverse events, and the need for dose adjustments.
Treatment: Placebo oil (MCT oil)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Potential Effects of Cannabigerol in Adolescents With Attention-Deficit/Hyperactivity Disorder: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial (CAN-ADHD)
- Criteria questions
- Built from NCT07592390, who can take part
- Record updated
- 18 May 2026